Certara Faces Securities Investigation as Shares Plunge 19%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Should l Buy CERT?
Source: Globenewswire
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, indicating weakened competitiveness in the market.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance reflecting instability in market demand, which could adversely affect future revenue growth.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that may further impact the company's revenue structure and market positioning, increasing future uncertainties.
- Stock Price Volatility: Following the earnings report, Certara's stock price plummeted from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, indicating investor concerns about the company's outlook and a drop in market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.480
Low
9.00
Averages
12.11
High
16.00
Current: 4.480
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Certara Faces Securities Investigation as Shares Plunge 19%
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, indicating weakened competitiveness in the market.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance reflecting instability in market demand, which could adversely affect future revenue growth.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that may further impact the company's revenue structure and market positioning, increasing future uncertainties.
- Stock Price Volatility: Following the earnings report, Certara's stock price plummeted from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, indicating investor concerns about the company's outlook and a drop in market confidence.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in the RBC CM Global Healthcare Conference on May 19 at 9:30 a.m. ET, showcasing its leadership in drug development and attracting investor interest.
- Subsequent Conference Dates: The company will also attend William Blair's 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, further expanding its market presence.
- Webcast Availability: Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website and will be accessible for replay for at least 90 days thereafter, ensuring timely information access for investors.
- Company Background: Certara is a global leader in model-informed drug development, serving over 2,600 biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive influence in the industry.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, indicating significant challenges in customer demand that could impact future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', which may lead to decreased investor confidence in the company's future performance and negatively affect its stock price.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that could further impact the company's revenue structure and raise concerns among investors regarding its long-term strategy.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, reflecting the market's negative reaction to the company's financial health and potentially prompting more investors to seek legal recourse to protect their interests.
See More
Investigation into Certara Investor Losses
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, raising concerns among investors and potentially leading to further stock price declines.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed results in service performance, indicating instability in market demand that could impact future revenue growth.
- Execution Challenges: Certara highlighted execution and go-to-market challenges in its services business, with inconsistencies over the past few quarters exacerbating investor concerns about the company's future performance and potentially eroding investor confidence.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and investors who suffered losses from holding Certara stock may have opportunities to seek compensation through legal channels, further increasing market uncertainty.
See More
Certara Reports Q1 Revenue Inline with Expectations Amid Challenges
- Revenue Meets Expectations: Certara reported Q1 revenue of $106.9 million, aligning with Wall Street's expectation of $106.13 million, although adjusted earnings per share of $0.09 fell short of the $0.11 estimate, indicating pressure on profitability.
- Business Sale and Strategic Shift: The company completed the sale of its global medical writing and related regulatory services business to Veristat for $85 million in cash, which is expected to improve financial health and allow a focus on core growth areas.
- 2026 Earnings Guidance Cut: Certara has lowered its 2026 adjusted earnings guidance to a range of $0.35 to $0.41 per share from the previous $0.44 to $0.48, reflecting the impact of the divestiture on future revenues and market concerns about growth.
- Software vs. Services Revenue: While software revenue increased by 7% year-over-year to $49.7 million, services revenue declined by 4% to $57.2 million, highlighting execution and go-to-market challenges that the company expects to resolve in the second half of the year.
See More
Certara to Announce Q1 Earnings on May 11
- Earnings Announcement: Certara (CERT) is set to announce its Q1 2023 earnings on May 11 before market open, with consensus EPS estimate at $0.11, reflecting a 21.4% year-over-year decline, and revenue estimate at $106.1 million, indicating a modest 0.1% year-over-year growth.
- Performance Expectations: Over the past two years, Certara has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a relatively stable performance in meeting market expectations.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 8 downward adjustments, suggesting a cautious market outlook for Certara's future performance.
- Strategic Overhaul: The new CEO has indicated an operational overhaul, with plans to sell the regulatory and medical writing business for up to $135 million, while projecting revenue growth to remain flat to 4% by 2026, highlighting a strategic pivot in response to market conditions.
See More
Certara Faces Securities Investigation as Shares Plunge 19%
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, indicating weakened competitiveness in the market.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed service performance reflecting instability in market demand, which could adversely affect future revenue growth.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its service segment, a strategic shift that may further impact the company's revenue structure and market positioning, increasing future uncertainties.
- Stock Price Volatility: Following the earnings report, Certara's stock price plummeted from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, indicating investor concerns about the company's outlook and a drop in market confidence.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in the RBC CM Global Healthcare Conference on May 19 at 9:30 a.m. ET, showcasing its leadership in drug development and attracting investor interest.
- Subsequent Conference Dates: The company will also attend William Blair's 46th Annual Growth Stock Conference on June 2 and the Jefferies Global Healthcare Conference on June 3, further expanding its market presence.
- Webcast Availability: Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website and will be accessible for replay for at least 90 days thereafter, ensuring timely information access for investors.
- Company Background: Certara is a global leader in model-informed drug development, serving over 2,600 biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive influence in the industry.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, indicating significant challenges in customer demand that could impact future revenue growth.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', which may lead to decreased investor confidence in the company's future performance and negatively affect its stock price.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that could further impact the company's revenue structure and raise concerns among investors regarding its long-term strategy.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price fell from $6.31 on May 8 to $5.13 on May 11, a decline of approximately 19%, reflecting the market's negative reaction to the company's financial health and potentially prompting more investors to seek legal recourse to protect their interests.
See More
Investigation into Certara Investor Losses
- Declining Financial Performance: Certara reported a 4% year-over-year decline in service revenue to $57.2 million and a 14% drop in service bookings to $66.6 million in its Q1 2026 results, raising concerns among investors and potentially leading to further stock price declines.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, with mixed results in service performance, indicating instability in market demand that could impact future revenue growth.
- Execution Challenges: Certara highlighted execution and go-to-market challenges in its services business, with inconsistencies over the past few quarters exacerbating investor concerns about the company's future performance and potentially eroding investor confidence.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and investors who suffered losses from holding Certara stock may have opportunities to seek compensation through legal channels, further increasing market uncertainty.
See More
Certara Reports Q1 Revenue Inline with Expectations Amid Challenges
- Revenue Meets Expectations: Certara reported Q1 revenue of $106.9 million, aligning with Wall Street's expectation of $106.13 million, although adjusted earnings per share of $0.09 fell short of the $0.11 estimate, indicating pressure on profitability.
- Business Sale and Strategic Shift: The company completed the sale of its global medical writing and related regulatory services business to Veristat for $85 million in cash, which is expected to improve financial health and allow a focus on core growth areas.
- 2026 Earnings Guidance Cut: Certara has lowered its 2026 adjusted earnings guidance to a range of $0.35 to $0.41 per share from the previous $0.44 to $0.48, reflecting the impact of the divestiture on future revenues and market concerns about growth.
- Software vs. Services Revenue: While software revenue increased by 7% year-over-year to $49.7 million, services revenue declined by 4% to $57.2 million, highlighting execution and go-to-market challenges that the company expects to resolve in the second half of the year.
See More
Certara to Announce Q1 Earnings on May 11
- Earnings Announcement: Certara (CERT) is set to announce its Q1 2023 earnings on May 11 before market open, with consensus EPS estimate at $0.11, reflecting a 21.4% year-over-year decline, and revenue estimate at $106.1 million, indicating a modest 0.1% year-over-year growth.
- Performance Expectations: Over the past two years, Certara has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a relatively stable performance in meeting market expectations.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 8 downward adjustments, suggesting a cautious market outlook for Certara's future performance.
- Strategic Overhaul: The new CEO has indicated an operational overhaul, with plans to sell the regulatory and medical writing business for up to $135 million, while projecting revenue growth to remain flat to 4% by 2026, highlighting a strategic pivot in response to market conditions.
See More
